Clinical Study Of PD-1 Inhibitor Combined With Chemotherapeutics In The Treatment Of Advanced Non-small Cell Lung Cancer

Background:In recent years,the main treatment for patients with advanced non-small cell lung cancer(NSCLC)is chemotherapy,but traditional chemotherapy regimens have more toxic and side effects and are more serious.In order to optimize treatment methods,tumor immunotherapy has gradually become an important research direction of anti-tumor therapy.Programmed cell death receptor 1(PD-1)/programmed death receptor 1 ligand 1(PD-L1)inhibitors can make T lymphocytes immune to tumors in a variety of ways.Sintilizumab is a domestic PD-1 inhibitor,but the current research on the drug for the treatment of advanced NSCLC is still insufficient.OBJECTIVE:Clinical study of PD-1 inhibitor combined with chemotherapeutics in the treatment of advanced non-small cell lung cancer.METHODS:From March 2018 to December 2020,40 patients with advanced NSCLC admitted to the First Hospital of Jilin University were selected,and the control group and the observation group each had 20 patients.All patients in the control group were treated with platinum-containing drugs based chemotherapy,and the patients in the observation group were treated with platinum-containing drugs combined with sintilimab.Both groups were given treatment for 6 courses.After 6 courses of treatment,the clinical treatment effect,T lymphocyte subsets,quality of life scores of the two groups of patients were compared,and the occurrence of adverse reactions during the treatment of the two groups of patients was observed.Results:The clinical efficacy of the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).The CD3+T cell score,CD4+T cell score,CD8+T cell score,CD4+/CD8+T cell ratio after treatment in the observation group were all higher than before treatment,and the difference was statistically significant(P<0.05).Comparison of CD3+T cell score,CD4+T cell score,CD8+T cell score,CD4+/CD8+T cell ratio after treatment in the observation group with the control group after treatment,the observation group is higher than the control group and the difference is statistically significant(P<0.05).Physical function(PF),role function(RF),cognitive function(CF),emotional function(EF),social function(SF),overall health status(QL)scores of patients in the observation group after treatment and the quality of life of cancer patients The total score of the scale(QLQ-C30)was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no difference in the incidence of toxicity between the two groups of patients during the treatment period,and the difference was not statistically significant(P>0.05).CONCLUSIONS:Sintilimab combined with chemotherapy drugs has a better clinical effect than chemotherapy alone in the treatment of patients with advanced NSCLC.It can improve the immune function of the patient and improve the quality of life,but the side effects are no different from chemotherapy alone.